Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.33 USD
Change Today -0.62 / -5.66%
Volume 706.9K
INFI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2015

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2015., at 08:30 US Eastern Standard Time. Location: 784 Memorial Drive.

Infinity Pharmaceuticals, Inc. Announces New Clinical Data for Duvelisib

Infinity Pharmaceuticals, Inc. announced new clinical data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with treatment-naïve chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy (blood cancer). Data from the Phase 1 study showed that duvelisib was highly active in this patient population cohort, with an overall response rate of 88% as defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, including 15 partial responses among 17 efficacy evaluable patients. These data will be presented at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on Sunday, May 31, 2015. The company also announced new translational data demonstrating that treatment with duvelisib resulted in a decrease in key mediators known to be involved in the communication between CLL cells and the tumor microenvironment. These data further support the investigation of dual inhibition of PI3K-delta and PI3K-gamma with duvelisib as a therapeutic strategy for the treatment of CLL.

Infinity Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:30 PM

Infinity Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Infinity Pharmaceuticals, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 08:50 AM

Infinity Pharmaceuticals, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 08:50 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.

Infinity Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM

Infinity Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $10.33 USD -0.62

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.02 USD +0.07
Curis Inc $3.28 USD -0.03
Evotec AG €3.33 EUR +0.274
Exelixis Inc $3.49 USD -0.27
GlaxoSmithKline SAE £11.50 EGP 0.00
View Industry Companies
 

Industry Analysis

INFI

Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.